<DOC>
	<DOCNO>NCT00888511</DOCNO>
	<brief_summary>The trial phase II study daily Tarceva combine definitive radiotherapy inoperable locally advanced non small cell lung cancer ( stage IIB-IIIB ) . The objective phase II trial examine Tarceva concomitant curatively intend irradiation 66 Gy ( 2 Gy x 33 F , 5 F per week ) .</brief_summary>
	<brief_title>Tarceva And Radiotherapy Locally Advanced Lung Cancer Non-small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Age ≥18 year Patients histologically cytologically document diagnosis locally advance NSCLC stage IIB IIIB without pleural effusion Performance status ≤2 ECOG scale Serum bilirubin must ≤1.5 upper limit normal ( ULN ) ALAT ≤2 x ULN Able comply study followup procedure Patients reproductive potential must use effective contraception Written ( sign ) inform consent participate study Any unstable systemic disease ( include active infection , unstable angina , congestive heart failure , severe hepatic , renal , metabolic disease ) Any malignancy within 5 year ( except adequately treat carcinoma situ cervix basal squamous cell skin cancer ) Inability take oral medication , requirement intravenous alimentation Nursing mother</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Lung cancer</keyword>
	<keyword>Non-small cell lung cancer</keyword>
	<keyword>Tarceva</keyword>
	<keyword>Radiotherapy</keyword>
	<keyword>Local-regionally advanced non-small cell lung cancer</keyword>
</DOC>